Who We Are

Akrotome is a Delaware corporation, first incorporated late 2008; the current team has been in place since 2012.

Our Focus

We are dedicated to the clinical translation of cancer-targeted molecular probes into enhanced approaches for surgery and diagnostics, leading to improved outcomes and patient quality of life while positively impacting healthcare economics.

How We Are Different

Akrotome’s molecular probes were designed from the ground up with an emphasis on the real-world requirements of cancer surgeons and the clinical workflow in the Operating Room. The result is a family of probes that offer superior performance, economics, and flexibility to other molecular probes on market.

While other probes use a “one size fits all” approach that requires systemic administration of large doses of probe hours or even days before surgery, Akrotome’s probes can meet a surgeon’s preference for an individual surgery, supporting the following application methods:

In vivo with topical administration
In vivo with systemic administration
Ex vivo with topical administration

In addition, Akrotome probes are quenched and do not activate until they encounter cancer, virtually eliminating the background fluorescence common with other probes.

This flexibility translates into real and quantifiable benefits, including: reduced regulatory risk and expense; faster time to market, and potential lower-per-use cost/enhanced profitability.

Akrotome Co-Founder Makes International Presentations

Contact supplier